Some Ebola patients need to forgo potentially life-saving treatments so researchers can see how they fare compared to people who get the experimental drugs, a Food and Drug Administration official said today. While randomized trials would be "challenging," they're needed to understand whether or how well the medicines work, said Edward Cox, director of the FDA's Office of Antimicrobial Products, at an American Society of Tropical Medicine and Hygiene conference in New Orleans. Trials would compare "the best supportive care versus the best supportive care with a drug," he said.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
